SCHEMBL2069374

SCHEMBL2069374

Cc1nc(-c2ccc(Cl)cc2)sc1C(=O)NCC1CN(c2ccccc2C(=O)O)CCO1

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 9/20 0.73
CHRM4 P08173 2/20 0.51
GAA P10253 1/20 0.46
PPARD Q03181 2/20 0.46
PPARG P37231 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.45
KDM4E B2RXH2 1/20 0.45
POLB P06746 1/20 0.45
RAB9A P51151 1/20 0.45
HPGD P15428 1/20 0.44
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
DGAT1 O75907 1/20 0.42
XDH P47989 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2069716 0.90 PPARA (0.63) PPARACHRM4GAAPPARDPPARG
SCHEMBL2070819 0.85 PPARA (0.73) PPARACHRM4GAAPPARDPPARG
SCHEMBL2069034 0.85 PPARA (0.73) PPARACHRM4GAAPPARDPPARG
SCHEMBL2069036 0.85 PPARA (0.73) PPARACHRM4GAAPPARDPPARG
SCHEMBL2069611 0.80 PPARA (0.86) PPARACHRM4PPARDPPARG
SCHEMBL27678409 0.79 PPARA (0.73) PPARACHRM4PPARDPPARGSMN1; SMN2
SCHEMBL2069727 0.78 PPARA (0.65) PPARACHRM4GAAPPARDPPARG
SCHEMBL2069412 0.77 PPARA (0.61) PPARACHRM4GAAPPARDPPARG
SCHEMBL2069330 0.77 PPARA (0.66) PPARACHRM4GAAPPARDPPARG
SCHEMBL2069990 0.77 PPARA (0.67) PPARACHRM4GAAPPARDPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
EP-1780210-A1 NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE Kyorin Pharmaceutical Co., Ltd. (JP) 2007-05-02 EP disclosed
EP-1780210-A1 NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE Kyorin Pharmaceutical Co., Ltd. (JP) 2007-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative PPARA, PPARG, PPARD PPARA 1/4885CHRM4 966/4885GAA 3876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.